Failure To Achieve pCR: Offer Capecitabine for TNBC

EDITORIAL BOARD

Steven Vogl, MD

Medical Oncologist
New York City

S-J Lee presented a groundbreaking Japanese-Korean trial (JBCRG-04 or CREATE-X, [Capecitabine for Residual cancer as Adjuvant ThErapy]) at the 2015 annual meeting of the San Antonio Breast Cancer Symposium seeking to tell oncologists what to do if a patient still has obvious cancer in the breast or nodes after neoadjuvant chemotherapy.¹ If their cancers fail to achieve pathologic complete